My Account
Amgen
SYMBOL:AMGN|SECTOR:Health Care|DERIVED:CFD
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices are indicative only and not appropriate for trading purposes. Therefore Moneycontrol doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
$93562
9
3
.
5
6
2
-3.61 (-1.34%)
As on 18 Nov, 2023 | 02:29 IST
Day Range
264.60
269.41
LH
52 Week Range
211.71
291.60
LH
| Open | 269.00 |
| Previous Close | 269.00 |
| Beta | 0.45 |
| High | 269.41 |
| Low | 264.60 |
| TTM EPS See historical trend | 17.42(+3.39% YoY) |
| 52 Week High | 291.60 |
| 52 Week Low | 211.71 |
| TTM PE See historical trend | 15.23(High PE) |
| Mkt. Cap ($ Billion) | 142.00 |
| Dividend Yield | 3.52 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
Moving Averages
| Days | |
|---|---|
| 5 | 269.01 |
| 10 | 269.36 |
| 20 | 268.12 |
| 50 | 269.61 |
| 100 | 256.63 |
| 200 | 245.28 |
Returns
Price Performance
| 1 Week | -0.74% | |
| 1 Month | -6.71% | |
| 3 Months | 0.56% | |
| YTD | 1.06% | |
| 1 Year | -7.64% | |
| 3 Years | 14.15% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 592.70 | 0.67 | 561.88 | 73.16 | 8.09 | 1.21 | 629.97/302.14 | -2.70 | Very Bullish |
| J&J | 149.74 | -0.24 | 360.73 | 14.73 | 10.17 | 2.92 | 181.04/144.95 | -4.00 | Bearish |
| Merck | 101.79 | -0.20 | 258.17 | 13.60 | 7.48 | 3.20 | 119.65/96.36 | -2.33 | Very Bearish |
| AbbVie | 138.13 | -0.11 | 244.16 | 11.60 | 11.92 | 4.39 | 168.11/130.96 | -7.27 | Very Bearish |
| Pfizer | 29.90 | 0.44 | 168.98 | 4.51 | 6.63 | 3.66 | 54.93/28.96 | -8.61 | Very Bearish |
Market news
- Dow weighed down by Walmart, Cisco SystemsNovember 17, 2023 6:29 AM
- Wall Street gains on easing inflation, Target's upbeat forecastNovember 16, 2023 6:15 AM
- Wall Street surges on news of cooling US inflationNovember 15, 2023 6:30 AM
- Wall Street mixed ahead of key US inflation dataNovember 14, 2023 7:12 AM
About the company
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq). It focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.